Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults

DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity

(2013) Ilin Chuang et al.   PLoS One

Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and Adenovirus (Ad5) immune mice

(2012) Nathaniel J Schuldt et al.   MALARIA JOURNAL

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Malaria vaccines: Focus on adenovirus based vectors

(2012) Nathaniel J. Schuldt et al.   VACCINE

A Peptide-BasedPlasmodium falciparumCircumsporozoite Assay To Test for Serum Antibody Responses to Pre-Erythrocyte Malaria Vaccines

(2011) Stefan Kostense et al.   Clinical and Vaccine Immunology

Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children

(2011) Philip Bejon et al.   JOURNAL OF INFECTIOUS DISEASES

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

(2011) Ally Olotu et al.   LANCET INFECTIOUS DISEASES

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria

(2011) Ally Olotu et al.   PLoS One

Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults

(2011) Martha Sedegah et al.   PLoS One

Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

(2011) Cindy Tamminga et al.   PLoS One

Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial

(2011) Pedro Aide et al.   VACCINE

The Th1 Immune Response to Plasmodium falciparum Circumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous Insert

(2010) K. Radosevic et al.   Clinical and Vaccine Immunology

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)

(2010) Laurence Peiperl et al.   PLoS One

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

(2010) J.E. Ledgerwood et al.   VACCINE

Antibodies to Pre‐erythrocyticPlasmodium falciparumAntigens and Risk of Clinical Malaria in Kenyan Children

(2008) Chandy C. John et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis

(2008) M Juliana McElrath et al.   LANCET

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

(2008) Philip Bejon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice

(2008) Joseph P. Shott et al.   VACCINE